Abstract |
Our study of 39 patients with rheumatoid arthritis suggests a trend for benoxaprofen therapy given over a prolonged period to retard the rheumatologic process when measured radiologically by both osseous defect and joint space narrowing rates. After a mean duration of 21 months, the progression of osseous defects (OD) and/or joint space narrowing (JSN) was decreased in 28 of 39 patients (72%) who qualified for this study. Fourteen patients (36%) had both OD and JSN rates decreased. An additional 8 patients had OD rate diminished alone and another 6 patients had JSN decreased alone. Clinical evaluation of benoxaprofen has previously revealed a low risk factor and an ability to improve clinical symptoms and signs. Because there is also a trend for this drug to retard or arrest radiologic progression, it becomes a promising agent for the long-term treatment of rheumatoid arthritis.
|
Authors | G B Bluhm, D W Smith, W M Mikulaschek |
Journal | European journal of rheumatology and inflammation
(Eur J Rheumatol Inflamm)
Vol. 5
Issue 2
Pg. 186-97
( 1982)
ISSN: 0140-1610 [Print] England |
PMID | 7044795
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Propionates
- benoxaprofen
|
Topics |
- Anti-Inflammatory Agents
(therapeutic use)
- Arthritis, Rheumatoid
(diagnostic imaging, drug therapy)
- Clinical Trials as Topic
- Double-Blind Method
- Hand
(diagnostic imaging)
- Humans
- Propionates
(therapeutic use)
- Radiography
- Time Factors
|